Dr Marie Dezelic, PHD, LMHC | |
2655 S Le Jeune Rd Ste 537, Coral Gables, FL 33134-5832 | |
(305) 775-1031 | |
Not Available |
Full Name | Dr Marie Dezelic |
---|---|
Gender | Female |
Speciality | Counselor - Mental Health |
Location | 2655 S Le Jeune Rd Ste 537, Coral Gables, Florida |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1083236343 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103TC1900X | Psychologist - Counseling | (* (Not Available)) | Secondary |
101YM0800X | Counselor - Mental Health | MH13681 (Florida) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Marie Dezelic, PHD, LMHC 2655 S Le Jeune Rd Ste 537, Coral Gables, FL 33134-5832 Ph: () - | Dr Marie Dezelic, PHD, LMHC 2655 S Le Jeune Rd Ste 537, Coral Gables, FL 33134-5832 Ph: (305) 775-1031 |
News Archive
A new study presented today at The International Liver Congress 2015 shows that by using genomic analyses to understand how and when carcinogenic mutations occur in patients with hepatocellular carcinoma (HCC), it is possible to identify specific molecular profiles. It is hoped that these molecular profiles will help identify which patients would benefit from specific anticancer treatments.
On February 2, 2010, Speedus submitted an appeal regarding the Nasdaq staff determination by requesting a hearing with the Nasdaq Hearings Panel (the "Panel"). As a result, a hearing has been scheduled for March 11, 2010, at which time the Panel will consider the plan Speedus has developed for regaining and sustaining compliance with the Rule.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration has issued 510(k) clearance to the Simplexa Influenza A H1N1 (2009) test on the 3M Integrated Cycler. The Simplexa test, developed and manufactured by Quest Diagnostics' Focus Diagnostics business, is the first to be cleared by the FDA for use as an aid in the detection and differentiation of influenza A and 2009 H1N1 influenza viral RNA.
A cell-to-cell signaling network that serves as a developmental timer could provide a framework for better understanding the mechanisms underlying human heart valve disease, say University of Oregon scientists.
› Verified 6 days ago